Drug intelligence / Profile preview

PCSO-524

Development stage
Unknown
Lead developer
Pharmalink International
Modality
Small Molecules
Administration
Oral
01

Overview

PCSO-524 is a patented, stabilized lipid extract derived from the New Zealand green-lipped mussel (Perna canaliculus). It is primarily used as a natural anti-inflammatory supplement in veterinary medicine and as a dietary supplement for humans. The formulation contains a complex blend of over 90 free fatty acids, including omega-3 polyunsaturated fatty acids such as EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid), and ETA (eicosatetraenoic acid). Its mechanism of action involves inhibition of pro-inflammatory mediators, notably leukotriene B4 and prostaglandin E2 biosynthesis, as well as moderate inhibition of cyclooxygenase enzymes COX‑1 and COX‑2. This results in reduced production of inflammatory cytokines like TNF‑α and IFN‑γ. PCSO‑524 has demonstrated efficacy in reducing symptoms associated with osteoarthritis, atopic dermatitis, asthma, exercise-induced muscle soreness, and airway inflammation in both animal models and clinical studies[1][2][3][4][5][6].

Brand names
AntinolLyprinolOmega XL
Other names
New Zealand green-lipped mussel lipid extractPerna canaliculus lipid extract
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ALOX12 (Arachidonate 12-lipoxygenase, 12S type)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on PCSO-524.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCSO-524.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call